Go to the list of all blogs
Dem Sem's Avatar
published in Blogs
Jul 18, 2023
Trader Robot's Precision: BNGO Profits +2.90% in 7 Days

Trader Robot's Precision: BNGO Profits +2.90% in 7 Days

In this article, we will examine the performance of the AI trading robots accessible through "Swing trader: Top High-Volatility Stocks v.2 (TA)" and their recent success with BNGO, a high-volatility stock. While the bots generated a notable gain of +2.90% over the previous week, a closer look at BNGO's latest earnings report may signal a potential price pull-back in the near future.

AI Trading Bots Generate Impressive Gains with BNGO:

The AI trading robots accessible at "Swing trader: Top High-Volatility Stocks v.2 (TA)" showcased their capabilities by achieving a remarkable +2.90% gain while trading BNGO over the course of the previous week. This substantial return highlights the effectiveness of AI-driven strategies in capitalizing on the volatile movements of high-risk stocks.

Expectations of a Price Pull-Back:

Despite the recent gains, it's crucial for investors to exercise caution. Technical analysis suggests that a price pull-back in BNGO's value may be on the horizon. A price pull-back refers to a temporary decline in the stock's price after a notable rally, which could offer an opportunity for potential buyers to enter the market at a more favorable price point.

Analyzing BNGO's Earnings Report:

One of the key factors that might contribute to a potential price pull-back is BNGO's recent earnings report. On May 09, the company reported earnings per share of -10 cents, which fell short of the market estimate of -10 cents. This missed estimate could lead to a decrease in investor confidence and a subsequent dip in the stock's price.

Market Capitalization and Shares Outstanding:

As of the latest available data, BNGO has 6.25 million shares outstanding, resulting in a current market capitalization of 198.80 million dollars. Market capitalization reflects the total market value of a company's outstanding shares and can be a useful indicator of the company's size and overall market perception.

Conclusion:

The AI trading robots accessible through "Swing trader: Top High-Volatility Stocks v.2 (TA)" demonstrated their prowess by generating a significant +2.90% gain with BNGO during the previous week. However, investors should approach this success with caution, as technical analysis indicates the possibility of a price pull-back in the near future. The recent earnings report, where BNGO missed market estimates, may contribute to a potential decline in the stock's value

Related Ticker: BNGO

Contributor

Dem Sem's AvatarDem Sem|Expert

BNGO in downward trend: price expected to drop as it breaks its higher Bollinger Band on August 11, 2026

BNGO broke above its upper Bollinger Band on August 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 28 similar instances where the stock broke above the upper band. In of the 28 cases the stock fell afterwards. This puts the odds of success at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNGO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for BNGO entered a downward trend on August 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 07, 2026. You may want to consider a long position or call options on BNGO as a result. In of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BNGO just turned positive on August 06, 2026. Looking at past instances where BNGO's MACD turned positive, the stock continued to rise in of 39 cases over the following month. The odds of a continued upward trend are .

BNGO moved above its 50-day moving average on August 07, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for BNGO crossed bullishly above the 50-day moving average on August 14, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BNGO advanced for three days, in of 217 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.447) is normal, around the industry mean (5.071). P/E Ratio (0.002) is within average values for comparable stocks, (146.796). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.307). Dividend Yield (0.000) settles around the average of (0.017) among similar stocks. P/S Ratio (0.379) is also within normal values, averaging (91.060).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BNGO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNGO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 8.59B. The market cap for tickers in the group ranges from 126 to 133.83B. ISRG holds the highest valuation in this group at 133.83B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -0%. For the same Industry, the average monthly price growth was 11%, and the average quarterly price growth was 6%. FEMY experienced the highest price growth at 29%, while NXGL experienced the biggest fall at -42%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 9%. For the same stocks of the Industry, the average monthly volume growth was -18% and the average quarterly volume growth was -36%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 60
Price Growth Rating: 50
SMR Rating: 83
Profit Risk Rating: 95
Seasonality Score: -9 (-100 ... +100)
View a ticker or compare two or three
BNGO
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a developer of technologies for analysis of large biological molecules

Industry PharmaceuticalsOther

Profile
Details
Industry
Biotechnology
Address
9540 Towne Centre Drive
Phone
+1 858 888-7600
Employees
97
Web
https://www.bionano.com
Interact to see
Advertisement
Quantum Computing Inc. completed a $110 million acquisition of Luminar Semiconductor on February 2, significantly strengthening its photonics and manufacturing capabilities. Shares have traded with elevated volatility, peaking near $12.70 in mid-January before retreating to the $9 range amid heavy volume.
ERII shares have remained resilient, trading near $15.47 ahead of Q4 and full-year 2025 earnings scheduled for February 25, 2026. Q3 2025 results exceeded expectations, with revenue of $32 million and EPS of $0.07, despite year-over-year declines tied to project timing.
Liberty Broadband Corporation (LBRDA) has experienced pronounced swings in recent weeks, touching multiyear lows before staging a sharp recovery. The stock continues to trade within a wide 52-week range, closely tied to the value of its Charter Communications stake and investor expectations around the proposed merger.
Apollo Global Management (APO), a leading alternative asset manager, reports Q4 and full-year 2025 results on February 9, 2026, before the market opens. The firm has delivered a year of strong growth, with AUM expanding on record inflows exceeding $200 billion and origination surpassing $300 billion.
Arm Holdings (ARM) shares have demonstrated resilience in recent sessions, rebounding after an initial earnings-related pullback and stabilizing near technical support levels. While smartphone-related headwinds tied to memory shortages pressured sentiment, momentum in AI-driven data center royalties helped restore confidence.
Shell plc (SHEL) reported Q4 2025 adjusted earnings of $3.3 billion, below expectations due to weaker oil prices and non-cash tax charges. Full-year adjusted earnings reached $18.5 billion, supported by strong LNG and upstream operations. A 4% dividend increase to $0.372 per share and a new $3.5 billion buyback program reinforce capital return commitments.
Linde (LIN) reported Q4 2025 adjusted EPS of $4.20, topping estimates, with full-year revenue reaching $34 billion. 2026 EPS guidance of $17.40–$17.90 implies 6–9% growth, supported by a record $10 billion project backlog.
ConocoPhillips (COP) reported Q4 2025 adjusted EPS of $1.02, missing estimates due to weaker oil prices. Full-year adjusted earnings totaled $7.7 billion, with $19.9 billion in operating cash flow. Shares have gained more than 10% in recent weeks, supported by analyst upgrades and sector momentum.
Intercontinental Exchange (ICE) has navigated recent market volatility while remaining within its 52-week range. Broader weakness in financial data and exchange operators has created short-term pressure, but ICE’s diversified business model continues to provide stability.
Verisk Analytics (VRSK) delivered Q4 2025 revenue of $779 million, up 5.9% year over year, with adjusted EPS of $1.82, beating expectations. Booz Allen Hamilton (BAH) reported Q3 FY2026 revenue of $2.62 billion, down 10.2% year over year, but adjusted diluted EPS climbed 14% to $1.77, well above estimates.
(OMC) Omnicom’s fourth-quarter report, released February 18, 2026, marked its first earnings update incorporating results from Interpublic Group (IPG), acquired on November 26, 2025. The combination created the world’s largest marketing services firm by revenue, a significant milestone as the advertising industry consolidates and adapts to digital transformation.
Copart (CPRT) is set to report fiscal Q2 2026 earnings on February 19, 2026, after market close. Consensus calls for EPS of $0.39–$0.40 and revenue of $1.15–$1.18 billion. Global Payments (GPN) posted Q4 2025 adjusted EPS of $3.18, in line with expectations, and adjusted net revenue of $2.32 billion, up 6% in constant currency (excluding dispositions). Thomson Reuters (TRI) delivered Q4 2025 adjusted EPS of $1.07 and revenue of $2.01 billion, up 5% year over year, supported by recurring subscription growth.
Unilever PLC (UL) leads year-to-date performance with a 12.61% gain, ahead of Diageo plc (DEO) at 9.90% and Keurig Dr Pepper Inc. (KDP) at 4.27%. DEO offers the highest dividend yield at 4.35%, compared with KDP (3.16%) and UL (2.97%). All three stocks carry low betas—DEO (0.18), UL (0.24), and KDP (0.35)—highlighting their defensive characteristics.
Q1 Fiscal 2026 Results: Revenue of $333M and adjusted EBITDA of $50M (15% margin), exceeding analyst expectations. FY2026 Guidance Raised: Adjusted EBITDA now projected at $225M, with revenue reaffirmed near $1.5B. EV Backlog Growth: 855 electric buses worth $277M, highlighting robust demand supported by EPA clean bus funding.
IBM fell over 10% today mainly because a new AI tool from Anthropic is seen as a direct threat to IBM’s lucrative COBOL modernization and consulting business, triggering worries that key legacy‑modernization revenue will be automated away.
Today’s drop is mainly about competitive positioning and future growth expectations, not an immediate collapse of current Wegovy/Ozempic sales, but it signals that Novo may not have the strongest next‑wave obesity drug versus Eli Lilly, which is why the stock sold off so sharply.
RNG (RingCentral) dropped over 12% today mainly as a sharp pullback after a very steep recent run‑up driven by upbeat Q4 results, guidance, and capital‑return news, with profit‑taking amplified by valuation concerns and a weak broader tech tap
Fundamentally, the latest public guidance is still for rapid growth and profitability, but today’s drop reflects a reset of sentiment and valuation rather than a brand‑new deterioration in those targets. For investors, the key question is whether the current price appropriately reflects execution risk, competition in diagnostics, and macro volatility after the guidance‑driven rally and subsequent reversal.
TNC (Tennant Company) is down more than 25% today because it reported a very large earnings and revenue miss for Q4 2025, blamed on serious ERP rollout problems and weaker demand, and guided to a slower‑than‑hoped recovery in 2026.
XMTR (Xometry) is down more than 21% today because, despite reporting record growth and an earnings beat, the company announced a CEO transition and investors used the news to take profits after a big prior run‑up, with heavy short interest amplifying the drop.